International Biotechnology (Ordinary Share) IBT

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

506.00

Share Price

436.09

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
International Biotechnology (Ordinary Share) Price 72.98%
International Biotechnology (Ordinary Share) NAV 69.14%
FTSE World 21.53%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 440.3 -13.0% 506.00 506.00
25 May
100%

Discrete performance % over

Fund / BenchmarkJun '13
May '14
Jun '14
May '15
Jun '15
May '16
International Biotechnology (Ordinary Share) Price6.04100.10-18.47
International Biotechnology (Ordinary Share) NAV11.6884.35-17.85
FTSE World4.0116.600.22

Discrete performance over

Discrete Performance

Top 10 Holdings

Amgen Inc 8.53%
Biogen Idec Inc., 8.53%
Celgene Corporation 8.13%
Gilead Sciences Inc 7.03%
Regeneron Pharmaceuticals, Inc. 6.63%
Alexion Pharmaceuticals, Inc. 3.71%
Genmab 3.71%
Ophthotech 2.91%
Vertex Pharmaceuticals 2.91%
Chimerix 2.61%

Sectors weighting

Biotechnology 99.60%
Net Current Assets 0.40%

Regional weighting

North America Region 80.00%
Europe Developed ex-UK 13.00%
UK 6.00%
Cash/Cash Equivalent 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 31 Mar 1994
  • Currency GBX
  • Domicile UK
  • Share Price 436.09
  • Share Type Ordinary Share
  • TIDM IBT
  • ISIN GB0004559349
  • Shares Issued (M) 38
  • Market Capital (£M) 168.81
  • Gross Assets (£M) 196.60
  • Net Assets (£M) 196.60
  • TER (%) 1.65
  • Last AGM 09 Dec 2015
  • Next AGM 09 Dec 2016
  • Last Annual Report Date 06 Nov 2015
  • Next due Report Date 29 Feb 2016
  • Next due Report Type I/R
  • Objective:

  • To achieve capital growth through investing in high growth, development stage biotechnology companies.
  • Management Group(s):

  • SV Life Sciences Managers LLP
  • Managed by:

  • Ailsa Craig Start: 01 Jan 2005
  • Carl Harald Janson Start: 02 Sep 2013
  • Kate Bingham Start: 01 Jan 2005
  • Management Contract & Fees:

    The Manager is entitled to a management fee payable monthly at 0.9% p.a. of the Company's NAV. The Investment Manager is entitled to an annual performance fee calculated as follows: The portfolio consists of two pools: quoted and unquoted. The fee on the quoted pool is 10% of relative outperformance above the pound sterling adjusted NASDAQ Biotech Index (£ NBI) plus a 0.5% hurdle. The fee on the unquoted pool is 20% of net realised gains, taking into account any unrealised losses but not unrealised gains. The payment of the performance fee is subject to the following limits: the maximum performance fee in any one year is 2% of the net assets as at the financial year end for the relevant period (the Performance Fee Cap). This Performance Fee Cap will be split pro-rata between the quoted and unquoted pool. Any performance fee that is earned in excess of the Performance Fee Cap in any performance period is carried forward and, in the case of the quoted pool proportion, used to offset future underperformance of the quoted portfolio for the current financial period plus two preceding periods. On termination of the Investment Manager other than for cause, any unpaid performance fees will become payable, subject to a cap of 4% of net assets for the performance period in which the Investment Manager's appointment is terminated. This will allow the Investment Manager to be paid any historic fees that were previously deferred. The performance fee will no longer be subject to a high water mark on the quoted portfolio. If after accounting for any carried forward underperformance and adding back any carried forward performance fees in a particular period, the current period's performance is still negative, no performance fee will be payable in that period. The Management Agreement is terminable by either party on 12 months' notice.